<DOC>
	<DOC>NCT02588625</DOC>
	<brief_summary>This is a two part study. The purpose of Part A is to determine if BMS-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using one dose of BMS-986020. The purpose of Part B is to determine if BMS-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using two different doses of BMS-986020.</brief_summary>
	<brief_title>A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma, Systemic</mesh_term>
	<mesh_term>Scleroderma, Diffuse</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Diagnosis of diffuse cutaneous systemic sclerosis for 60 months or less Men and women â‰¥ 18 years of age Ability to comply with birth control requirements Certain immunosuppressive agents are permitted Limited cutaneous systemic sclerosis or sine scleroderma Active ulcers on fingers Pulmonary arterial hypertension Any gastrointestinal surgery that may impact absorption of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>